Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis
Authors:
- 3 September 2014
- journal article
- Published by Wiley in Liver International
- Vol. 35 (1) , 37-45
Abstract
Background & Aims: Systemic inflammation in advanced cirrhosis represents a spectrum ranging from subclinical pathological bacterial translocation and immune activation to overt bacterial infection and sepsis. We hypothesized that systemic inflammation in cirrhosis is accompanied by a failure of ADAMTS13 to control the prothrombotic function of von Willebrand factor (VWF), which is increased in portal hypertension and hepatic fibrosis.Methods: Patients with Child A cirrhosis (n = 25), Child B/C cirrhosis without clinical features of systemic inflammation (n = 31), and Child B/C cirrhosis with overt bacterial infections or systemic inflammatory response syndrome (n = 24) were analysed for ADAMTS13 and associated parameters and were followed to determine transplant‐free survival.Results: Plasma concentration and activity of ADAMTS13 were decreased in patients with systemic inflammation. Furthermore, ADAMTS13 inversely correlated with the extent of bacterial translocation and the severity of acute‐phase reaction. As a function of reduced ADAMTS13 activity and increased VWF antigen, plasma from patients with superimposed inflammation strongly aggregated the platelet receptor glycoprotein Ib in presence of ristocetin. VWF:RCo correlated with higher concentrations of leucocytes and lipopolysaccharide‐binding protein, organ dysfunction, augmented turnover of cross‐linked intravascular fibrin, and the occurrence of acute kidney injury during follow‐up. VWF:RCo of 390% or more predicted transplant‐free survival in univariate analysis [HR = 8.24 (3.30–20.54)] and after adjustment for MELD [HR = 3.58 (1.30–9.88)]. However, adverse outcome was not associated with the accumulation of high‐molecular weight VWF multimers.Conclusions: Systemic inflammation complicating advanced cirrhosis is accompanied by reduced activity of ADAMTS13 promoting a prothrombotic function of VWF, which can be employed to predict clinical outcome.Keywords
Funding Information
- Federal Ministry of Education and Research (FKZ: 01 E0 1002)
- German Research Foundation (BR 4182/1-1)
- Jena Center for interdisciplinary research
This publication has 44 references indexed in Scilit:
- The augmented neutrophil respiratory burst in response toEscherichia coliis reduced in liver cirrhosis during infectionClinical and Experimental Immunology, 2011
- Increased production of ADAMTS13 in hepatic stellate cells contributes to enhanced plasma ADAMTS13 activity in rat models of cholestasis and steatohepatitisThrombosis and Haemostasis, 2009
- Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cellsJournal of Thrombosis and Haemostasis, 2008
- Comprehensive analysis of ADAMTS13 in patients with liver cirrhosisThrombosis and Haemostasis, 2008
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryCritical Care, 2007
- Increased ADAMTS‐13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivoJournal of Thrombosis and Haemostasis, 2006
- Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammationThrombosis and Haemostasis, 2005
- Platelet Activation and the Formation of the Platelet PlugArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangementHepatology, 2003
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992